X
Details:
Sanofi gains Kymab's KY1005 (Amlitelimab) to its pipeline, a fully human monoclonal antibody targeting key immune system regulator OX40L. Kymab’s pipeline also includes the oncology asset KY1044.
Lead Product(s): Amlitelimab
Therapeutic Area: Dermatology Product Name: KY1005
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Sanofi
Deal Size: $1,450.0 million Upfront Cash: $1,100.0 million
Deal Type: Acquisition April 09, 2021
EMWA 2024
Not Confirmed
Contact SupplierDetails:
The transaction will result in Sanofi having full global rights to KY1005, a fully human monoclonal antibody that has a novel mechanism of action. KY1005 binds to OX40-Ligand and has the potential to treat a varieties of immune-mediated diseases and inflammatory disorders.
Lead Product(s): Amlitelimab
Therapeutic Area: Dermatology Product Name: KY1005
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Sanofi
Deal Size: $1,450.0 million Upfront Cash: $1,100.0 million
Deal Type: Acquisition January 11, 2021
EMWA 2024
Not Confirmed
Contact Supplier
Details:
A clinically meaningful improvement in disease activity was found compared to placebo, as measured by percentage of change from baseline in the Eczema Area and Severity Index (EASI) in patients inadequately controlled by topical corticosteroids from baseline to week 16.
Lead Product(s): KY1005
Therapeutic Area: Dermatology Product Name: KY1005
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 11, 2020
EMWA 2024
Not Confirmed
Contact Supplier
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
